The Journal of Pediatrics
Volume 155, Issue 6 , Pages 795-800 , December 2009

Can Montelukast Shorten Prednisolone Therapy in Children with Mild to Moderate Acute Asthma? A Randomized Controlled Trial

  • Suzanne Schuh, MD, FRCPC

      Affiliations

    • Division of Pediatric Emergency Medicine, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada
    • Corresponding Author InformationReprint requests: Dr Suzanne Schuh, Division of Paediatric Emergency Medicine, The Hospital for Sick Children, 555 University Ave, Toronto, Ontario M5G 1X8, Canada.
    • ,
  • Andrew R. Willan, PhD

      Affiliations

    • Department of Pediatrics and Research Institute, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada
    • ,
  • Derek Stephens, MSc

      Affiliations

    • Department of Pediatrics and Research Institute, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada
    • ,
  • Paul T. Dick, MDCM, FRCPC

      Affiliations

    • Division of Pediatric Medicine, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada
    • ,
  • Allan Coates, MD, FRCPC

      Affiliations

    • Division of Respirology, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada

Received 8 January 2009 ,Revised 23 March 2009 ,Accepted 5 June 2009.

Refernces 

  1. Kozak LJ, Owings MF, Hall MJ. National Hospital Discharge Survey: 2002 annual summary with detailed diagnosis and procedure data. Vital Health Stat. 2005;13:1–199
  2. Ducharme FM, Chalut D, Plotnick L, Savdie C, Kudirka D, Zhang X, et al. The Pediatric Respiratory Assessment Measure: a valid clinical score for assessing acute asthma severity from toddlers to teenagers. J Pediatr. 2008;152:476–480
  3. Schuh S, Reisman J, Alshehri M, Dupuis A, Corey M, Arseneault R, et al. A comparison of inhaled fluticasone and oral prednisone for children with severe acute asthma. N Engl J Med. 2000;343:689–694
  4. National Asthma Education and Prevention Program. Expert Panel Report 2: guidelines for the diagnosis and management of asthma. Bethesda, MD: National Heart, Lung and Blood Institute; 1997;p. 4051
  5. Dolan LM, Keserwala HH, Holroyde JC, Fischer TJ. Short-term, high-dose, systemic steroids in children with asthma: the effect on the hypothalamic-pituitary-adrenal axis. J Allergy Clin Immunol. 1987;80:81–87
  6. Wolthers OD, Pedersen S. Short term linear growth in asthmatic children during treatment with prednisolone. BMJ. 1990;301:145–148
  7. Crain EF, Weiss KB, Fagan MJ. Pediatric asthma care in US emergency departments. Current practice in the context of the National Institutes of Health guidelines. Arch Pediatr Adolesc Med. 1995;149:893–901
  8. Knapp JF, Simon SD, Sharma V. Quality of care for common pediatric respiratory illnesses in United States emergency departments: analysis of 2005 National Hospital Ambulatory Medical Care Survey Data. Pediatrics. 2008;122:1165–1170
  9. Spector S. Noncompliance with asthma therapy—are there solutions?. J Asthma. 2000;37:381–388
  10. Butler K, Cooper WO. Adherence of pediatric asthma patients with oral corticosteroid prescriptions following pediatric emergency department visit or hospitalization. Pediatr Emerg Care. 2004;20:730–735
  11. Wardlaw AJ, Hay H, Cromwell O, Collins JV, Kay AB. Leukotrienes, LTC4 and LTB4, in bronchoalveolar lavage in bronchial asthma and other respiratory diseases. J Allergy Clin Immunol. 1989;84:19–26
  12. Drazen JM, O'Brien J, Sparrow D, Weiss ST, Martins MA, Israel E, et al. Recovery of leukotriene E4 from the urine of patients with airway obstruction. Am Rev Respir Dis. 1992;146:104–108
  13. Green SA, Malice MP, Tanaka W, Tozzi CA, Reiss TF. Increase in urinary leukotriene LTE4 levels in acute asthma: correlation with airflow limitation. Thorax. 2004;59:100–104
  14. Bisgaard H. Leukotriene modifiers in pediatric asthma management. Pediatrics. 2001;107:381–390
  15. Knorr B, Nguyen HH, Kearns GL, Villaran C, Boza ML, Reiss TF, et al. Montelukast dose selection in children ages 2 to 5 years: comparison of population pharmacokinetics between children and adults. J Clin Pharmacol. 2001;41:612–619
  16. Global Initiative for Asthma. Global strategy for asthma management and prevention 2003. Bethesda, MD: National Institute of Health; 2003;Publication No. 02-3659
  17. Knorr B, Franchi LM, Bisgaard H, Vermeulen JH, LeSouef P, Santanello N, et al. Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. Pediatrics. 2001;108:E48
  18. Camargo CA, Smithline HA, Malice MP, Green SA, Reiss TF. A randomized controlled trial of intravenous montelukast in acute asthma. Am J Respir Crit Care Med. 2003;167:528–533
  19. Silverman RA, Nowak RM, Korenblat PE, Skobeloff E, Chen Y, Bonuccelli CM, et al. Zafirlukast treatment for acute asthma: evaluation in a randomized, double-blind, multicenter trial. Chest. 2004;126:1480–1489
  20. Harmanci K, Bakirtas A, Turktas I, Degim T. Oral montelukast treatment of preschool-aged children with acute asthma. Ann Allergy Asthma Immunol. 2006;96:731–735
  21. Robertson CF, Price D, Henry R, Mellis C, Glasgow N, Fitzgerald D, et al. Short-course montelukast for intermittent asthma in children: a randomized controlled trial. Am J Respir Crit Care Med. 2007;175:323–329
  22. Becker AB, Nelson NA, Simons FE. The pulmonary index. Assessment of a clinical score for asthma. Am J Dis Child. 1984;138:574–576
  23. Santanello NC, Davies G, Galant SP, Pedinoff A, Sveum R, Seltzer J, et al. Validation of an asthma symptom diary for interventional studies. Arch Dis Child. 1999;80:414–420
  24. Willan AR. Power function arguments in support of an alternative approach for analyzing management trials. Control Clin Trials. 1994;15:211–219
  25. Geller NL, Pocock SJ. Interim analyses in randomized clinical trials: ramifications and guidelines for practitioners. Biometrics. 1987;43:213–223
  26. Altamimi S, Robertson G, Jastaniah W, Davey A, Dehghani N, Chen R, et al. Single-dose oral dexamethasone in the emergency management of children with exacerbations of mild to moderate asthma. Pediatr Emerg Care. 2006;22:786–793
  27. Peters SP. Leukotriene receptor antagonists in asthma therapy. J Allergy Clin Immunol. 2003;111(1 Suppl):S62–S70
  28. Hui KP, Barnes NC. Lung function improvement in asthma with a cysteinyl-leukotriene receptor antagonist. Lancet. 1991;337:1062–1063
  29. Kuitert LM, Barnes NC. Leukotriene receptor antagonists: useful in acute asthma?. Thorax. 2000;55:255–256
  30. Nelson KA, Smith SR, Trinkaus K, Jaffe DM. Pilot study of oral montelukast added to standard therapy for acute asthma exacerbations in children aged 6 to 14 years. Pediatr Emerg Care. 2008;24:21–27
  31. Malavige GN. Why glucocorticoids are better than leukotriene receptor antagonists. BMJ. 2003;326:621
  32. Lima JJ, Zhang S, Grant A, Shao L, Tantisira KG, Allayee H, et al. Influence of leukotriene pathway polymorphisms on response to montelukast in asthma. Am J Respir Crit Care Med. 2006;173:379–385
  33. Bronsky EA, Kemp JP, Zhang J, Guerreiro D, Reiss TF. Dose-related protection of exercise bronchoconstriction by montelukast, a cysteinyl leukotriene-receptor antagonist, at the end of a once-daily dosing interval. Clin Pharmacol Ther. 1997;62:556–561

 Funded as an investigator-initiated study by Merck Frosst Canada Ltd (S.S.). The funding organization had no role in design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript. The authors declare no conflicts of interest.

 Registered with www.clinicaltrials.gov (NCT00213252).

PII: S0022-3476(09)00553-8

doi: 10.1016/j.jpeds.2009.06.008

The Journal of Pediatrics
Volume 155, Issue 6 , Pages 795-800 , December 2009

Article Tools

* Image Usage & Resolution